ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Psychotropic medication use and bone fracture risk among patients with multiple sclerosis: a real-world study.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this global real-world study, psychotropic medications, particularly analgesics, were associated with increased risks of fractures (HR, 2.41; P < 0.001) and disease relapse (HR, 3.63; P < 0.001) in patients with multiple sclerosis. Interaction analyses further indicated a higher fracture risk among opioid users (HR, 3.83; P < 0.001). PURPOSE: Patients with multiple sclerosis (MS) frequently require psychotropic medications, yet their effects on fracture risk and disease activity remain unclear. This study evaluated the risks of fractures, MS relapse, and mortality associated with psychotropic medication use in patients with MS.
methodsWe conducted a global, retrospective cohort study using the TriNetX Research Network. Adult patients with MS were categorized into a psychotropics group and a control group. Propensity score matching in a 1:1 ratio was performed to balance baseline covariates. Primary outcomes included risks of all fractures (hip, vertebral, and extremity), MS relapse, and mortality assessed over a 5-year follow-up. Interaction analyses were performed to determine the differential effects of medication classes.
resultsAfter matching, 117,534 patients (58,777 per group) were included. At the 5-year follow-up, the psychotropic users exhibited significantly higher risks of all fractures (HR, 2.41; 95% CI 2.22-2.63; NNH, 49) and MS relapse (HR, 3.63; 95% CI 3.51-3.75; NNH, 6). No significant difference was observed in mortality. Interaction testing revealed that analgesic use was the primary contributor to fracture risk. Subgroup analysis further identified opioids as the high-risk agent (HR, 3.83; 95% CI 3.45-4.25; NNH, 24), whereas non-opioid analgesics showed no significant association with overall fracture risk.
conclusionsPsychotropic medication use was associated with increased fracture and relapse risk in multiple sclerosis, driven primarily by opioid analgesics, without an effect on mortality. Bone-conscious pain management and fall prevention should be prioritized.
Indexed as
Identifiers
41697311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.